Experts in health economics,
pricing and reimbursement
PHMR is an international team of highly qualified health economists and research scientists

The carefully curated multidisciplinary team at PHMR is comprised of highly qualified health economists and research scientists. This international collective of dedicated professionals provides in depth understanding of global markets and the capacity to work seamlessly in local languages.


Their combined insight from extensive industry specific experience in global pharmaceutical companies, academic positions and health economics consultancies ensures that PHMR’s clients always receive reliable, expert advice.

Mark Ratcliffe
Mark Ratcliffe
Mark is the founder of PHMR and has developed the company into a successful health economics, pricing and market access consultancy working with a range of top 10 pharma companies. He has a vast amount of experience in the health economics, pricing, reimbursement and market access fields. He also possesses decades of experience with major international pharmaceutical companies and previous work in senior economics research positions.
Louise Longworth
Louise Longworth
Louise has extensive experience in health economics and health technology assessment. She has in-depth experience in the methods of HTA and advises on the development of HTA strategy and evidence submissions in a wide range of therapeutic areas. Louise has specialist expertise in patient reported outcomes and utility measurement. She has been a member of the EuroQol Group, the organisation responsible for the development of the EQ-5D instruments, for most of her career and currently holds a position on the Board of Directors. She has held various roles with National Institute for Health and Care Excellence (NICE) including as Technical Adviser in the Technology Appraisals programme, leader of independent evidence reviews, member of its Decision Support Unit and as a member of its Technology Appraisal Committee. Louise has published extensively on health economics methodology and HTA policy.
Michael Lees
Michael is involved across a range of health economics, outcomes research and market access projects at PHMR and is responsible for ensuring that the research delivered matches the strategic needs of our clients. Michael has extensive experience in the development of health economic models and indirect treatment comparisons, utility measurement and health valuation, strategies for collection and use of real-world data, as well as the development of dossiers to support HTA submission. He also has substantial experience in working with different stakeholders, including through the use of early scientific advice through HTA agencies, to lead the development of integrated evidence plans and allow for access needs to be incorporated from early in product development. Michael has led projects across many different therapeutic areas, with expertise in fields including oncology, GI, neuroscience, rare disease, and cardiovascular disease. Michael has also published his research in peer-reviewed journals and presented work at multiple international conferences. He has led educational initiatives to shape HTA policy which involved delivering symposiums at international conferences and developing publications to support the use of innovative methodologies to demonstrate the value of new immuno-oncology medicines.
Cormac Sammon
Cormac Sammon
Cormac is an epidemiologist with several years’ experience of successfully delivering clinical and economic research projects for a variety of clients. His work has utilised real world data to contribute across the drug development process, from establishing the clinical and economic burden of disease to informing key parameters of cost-effectiveness models and monitoring the long-term post-marketing safety and effectiveness of drugs. Cormac’s expertise in generating and interpreting complex clinical and economic data and utilising it to demonstrate the value of emerging technologies has led him to successfully lead a broadening portfolio of HEOR projects, including systematic and pragmatic literature reviews, economic models, and HTA submissions for NICE, SMC and NCPE. He has been published extensively across a range of clinical, therapeutic and methodological areas.
Koonal Shah
Koonal is a health economist with expertise in stated preference methods, the measurement and valuation of health, and the use of social value judgements in HTA decision making. He has written extensively on patient-reported outcomes and HTA policy (focusing on the assessment of cancer and end of life treatments) and has published over 40 peer-reviewed journal articles and book chapters. He has led high-profile projects across a broad range of clinical and methodological areas, with his work on the generation and analysis of utility values used in a large number of HTA submissions. Koonal is a member of the EuroQol Group (an international network of researchers that developed the EQ-5D family of instruments) and currently serves on the Group’s Executive Committee. He is also an Honorary Research Fellow at the University of Sheffield’s School of Health and Related Research.
Donna Fountain
Donna Fountain
Donna has extensive experience of leading and delivering a wide range of to projects to support pharmaceutical companies with their health economics and outcomes research needs as well as maximising market access/reimbursement for new pharmaceutical and diagnostic interventions. She specialises in conducting systematic and targeted literature reviews to support HTA submissions and market access strategy, as well as global value dossier development, stakeholder engagement, reimbursement and landscape mapping, and peer-review manuscript development. Donna has extensive knowledge of multiple therapeutic areas, including oncology, chronic kidney disease, gastrointestinal disorders, cardiovascular disease, age-related disease, and orphan diseases. Donna has also published her research in peer-reviewed journals and presented work at multiple international conferences. Donna holds a PhD in Virology and Immunology from the University of Nottingham.
Matt Glover
Matt is a health economist with extensive experience in conducting economic evaluations of new treatments and specialises in long-term modelling, with knowledge of a variety of software and conceptual models. He has contributed to and advised biopharma clients on submissions to a number of HTA agencies. He has also contributed health economic input to the design of numerous randomised controlled trials and analysed and synthesised trial data.
Waqas Ahmed
Waqas is a health economist with a background in clinical pharmacy. Since joining PHMR, he has been involved in projects examining the content validity of a range of preference-based measures of health outcomes, as well as preference elicitation studies involving the person trade-off and discrete choice experiment methodologies. Waqas holds an MSc in Health Economics from the University of York.
Vlad Berdunov
Vlad is a health economist with substantial experience of leading cost-effectiveness and budget impact modelling projects. He has extensive knowledge of statistical methods applicable to economic evaluation through his experience in trial-based economic evaluation and decision-analytic modelling to support HTA submissions. Vlad has expertise in long-term modelling in rare diseases, including therapeutic areas with sparse evidence of long-term costs and benefits of treatment. His other research interests include the application of propensity scores to adjust for confounding in observational studies and the use of indirect comparisons of efficacy of treatments in the absence of head-to-head trials.
Megan Besford
Megan Besford
Since joining PHMR, Megan has conducted a wide range of statistical analyses such as indirect treatment comparisons and real-world evidence synthesis including network meta-analyses, matching-adjusted indirect comparisons and large patient-level health record analyses. She is experienced in many common and novel statistical methods used in the pharmaceutical industry and utilises both frequentist and Bayesian frameworks. She is also proficient with multiple programming languages including SAS, R and WinBUGS. Megan has published research in peer-reviewed journals and presented work at international conferences in a range of therapeutic areas including oncology, rare diseases and cardiology. Megan is a member of the Royal Statistical Society and is working towards Chartered Statistician status.
Lynsey Boyce
Lynsey is the scientific office manager and administrator at PHMR. Her extensive experience in the life sciences and with rapidly growing healthcare consultancies results in a skill set which bridges the gap between business and science. She is passionate about bringing PHMR’s values to life by facilitating and supporting the development of lasting client partnerships; the delivery of quality science with integrity; and the cultivation of a supportive, skill sharing environment. Her drive to optimise organisation and efficiency reinforces the delivery of PHMR’s consistently high standards.
Rebecca Brown
Rebecca has experience in project management in a variety of project types including HTA reviews and systematic, targeted and pragmatic reviews. Rebecca has extensive experience in performing reviews of clinical, economic, utilities and real-world evidence with the aim of supporting HTA submissions. Rebecca also has experience in preforming HTA reviews, as well as analysing pricing and reimbursement data to provide strategic recommendations. Rebecca has contributed to the writing of multiple manuscripts, abstracts, poster presentations and slide decks for a variety of audiences. She has experience in multiple disease areas including nutrition, ageing, gastrointestinal disease, musculoskeletal disease, and rare diseases. Rebecca holds a PhD in Ageing and Health from Newcastle University.
Gintare Cepinskaite
Gintare Cepinskaite
Gintare, Assoc CIPD, keeps HR operations aligned to the company values and brings the skills, knowledge and energy required to ensure PHMR is a great place to work.
Jasmine Farrington
Jasmine is experienced in developing and supporting HTA and market access strategy and has experience collaborating with national affiliates on behalf of our global clients. Jasmine provides project management and delivery for multiple aspects of HTA evidence generation, including systematic literature reviews, landscape analyses, HTA reviews, pricing research and engagements with key opinion leaders. Jasmine additionally contributes to PHMR’s operations and enjoys optimising organisation and communication for our projects to progress rapidly, efficiently and to the highest standards. Jasmine also has considerable experience in the analysis of HTA policy, including novel reimbursement frameworks for cell and gene therapies. Jasmine has over 10 years of experience in pharmacology, having previously worked in the UK and Europe for two world leading pharmaceutical companies. She has publications in several peer-reviewed journals and has presented her research at a range of international conferences.
India Flint
India Flint
India joined PHMR having successfully completed her MSc in Health Economics at the University of York. She has since managed a range of health economic and outcomes research projects. Her expertise enables her to conduct both quantitative and qualitative research, including mapping methods for estimation of health state utility, analysis of patient-reported outcomes, patient preference studies and the development and execution of feasibility assessments. She has also supported the building and reviewing of economic models such as cost-effectiveness and budget impact models. India has worked across a variety of disease areas, including rare diseases and epilepsy.
Lefteris Floros
Lefteris Floros
Lefteris has a broad knowledge of health economics having served in multiple academic and commercial positions. He holds extensive experience with the collection, evaluation, and modelling of clinical and cost data having led the development of multiple global and regional economic models for HTA submission purposes, and having designed numerous clinical trial-based economic evaluations. He also carries great familiarity with HTA agency processes having been a part of the technical teams supporting expert committees of UK NICE clinical guidelines and represented pharmaceutical clients in agency committee discussions. His experience also expands in the generation of comprehensive economic value stories for pharmaceutical products used in discussions with payers.
Daniella Foster
Daniella is involved in a variety of projects at PHMR, including the development of global value dossiers alongside systematic and targeted literature reviews which generate evidence for the purpose of HTA. Daniella has experience in several disease areas, including neurology, renal disease, and oncology. Daniella’s interest in market access across Europe has informed a variety of HTA projects and development of training materials, as well as the PHMR monthly market access alerts which aim to keep clients informed on HTA decisions and key updates in the UK, Germany and France.
Dave Fox
Dave Fox
Dave has considerable experience in the information and library field supporting health research. He is responsible for designing literature searches and strategies as well as managing the results of searches using reference management software to support the wide variety of projects and research that PHMR undertakes for clients. He has run literature searches to support numerous reviews including NICE single and multiple technology assessments, Cochrane reviews, Public Health Research Council projects, and British Thoracic Society clinical guidelines.
Louise Francis
Louise has considerable experience in all stages of systematic and targeted literature reviews to inform HTA and has worked on a broad range of projects in multiple disease areas, including oncology, neurology, and renal disease. Louise has a keen interest in value communications and has contributed to the development of several global value dossiers which help our clients demonstrate the value of their products. Louise is also involved in PHMR’s monthly market access alerts which allow clients to keep up to date with HTA decisions. Louise holds a PhD in Nutrition.
Adam Gibson
Adam is involved in a range of health economic and outcomes projects at PHMR. He brings a wealth of knowledge in conducting both quantitative and qualitative research in health valuation, utility measurement, patient and caregiver-reported outcomes, and psychometric testing. He has supported on projects across a range of indications such as oncology, musculoskeletal and rare disease, and psychological and mood disorders. Adam has contributed to the generation of evidence for outcomes dossiers and economic models, and advised on outcomes data collection for clinical trials. He has also published and presented research on patients’ treatment experiences at international conferences and in peer-reviewed journals.
Nicola Illingworth
Nicola Illingworth
Nicola has conducted focussed and pragmatic literature reviews and contributed to projects on clinical trial design and burden of illness studies, global HTA strategies and the use of patient reported outcome measures in HTA. Nicola has extensive experience in clinical trial method development and has developed skills in data extraction and data management, presenting reports in the form of slide decks or word documents, as well the preparation of manuscripts and posters.
Persefoni Ioannou
Persefoni Ioannou
Persefoni’s role at PHMR is to manage and deliver a wide range of projects in support of market access and reimbursement activities for pharmaceuticals and medical devices. She has extensive experience in value communications, focusing on building impactful value propositions and GVDs to communicate the product value and facilitate market access. Additionally, Persefoni has significant experience in HTA submissions, early drug pipeline assessments, advisory boards and systematic/pragmatic literature reviews. Persefoni has worked in a range of disease areas, including musculoskeletal diseases, gastrointestinal disorders, mental disorders, epilepsy, diabetes, and oncology. Persefoni holds a PhD in Duchenne muscular dystrophy from Newcastle University.
Gabriel Jones
Gabriel Jones
Involved in a range of projects, Gabriel has extensive experience of carrying out systematic and pragmatic literature reviews to support submissions to multiple European HTA agencies. He has also contributed to multiple reviews aiming to support the value proposition of technologies in global markets and help clients understand the value of their portfolio of products. Gabriel has worked on global value dossiers to support market access of technologies in Europe, North America and emerging markets, and HTA reviews to understand evidence requirements for approval and reimbursement of combination therapies and highly specialised treatments. Gabriel helped to develop PHMR's Market Access Alerts service and has been published in high-impact journals as well as having presented work at international conferences in the areas of oncology, endocrinology and infectious disease.
Ewan Laws
As a health economist, Ewan has been involved in the development of cost-effectiveness and budget impact models as well as survival modelling and data extrapolation, with experience of PRO studies and vignette utility generation. Ewan also has experience conducting systematic and targeted literature reviews alongside quantitative data analysis. He has particular therapeutic knowledge of NASH, immuno-oncologics, Hunter syndrome and Fabry disease.
Thomas Leahy
Thomas is a statistician and since joining PHMR has been involved in a variety of projects supporting market access through real-world evidence studies and indirect treatment comparisons. In particular, he has conducted several Bayesian network-meta analyses and matching-adjusted indirect comparisons in areas including cardiovascular disease, oncology and neurology. In addition, he has published work in peer-reviewed journals on the development of methodologies and in support of market access and post-market access activities. Thomas has been involved in the development of real-world evidence strategies and is proficient in R, STATA and Python programming languages.
Andrew Lenny
Andrew has been involved in a broad range of projects at PHMR, including the development, implementation and evaluation of health outcome measures and valuation surveys. Andrew’s knowledge has enabled him to advise clients on strategies for the generation of health-related utility data in rare disease areas to support their HTA submissions. In addition, Andrew has expertise in the methodologies used in the valuation of child health and has presented research in this area at international health economics and health outcomes conferences. His research experience spans a range of indications including oncology and lysosomal storage disorders. Andrew holds an MSc in Health Economics from the University of York.
Helen Lawrence
Helen Lilley
Helen leads the development of value propositions and global value dossiers. She has worked across a wide range of therapeutic areas, including oncology, chronic kidney disease, metabolic disorders, and bladder/bowel health. She is also experienced in conducting systematic literature reviews to support HTA submission and preparing HTA submission dossiers. Helen applies her expert medical writing skills to a broad range of projects at PHMR, including published manuscripts, posters and slide decks.
Ping-Ru Lo
Ping-Ru Lo
Ping has been with PHMR since its foundation helping it develop into a successful health economics, pricing and market access consultancy. Coming from a background in clinical pharmacy both in Germany and the UK, she has changed direction in order to lead the contracting and finance team and set up the internal project management structure.
Aurelie Meunier
Aurelie Meunier
Aurelie is a health economist with broad experience in economic evaluation, contributing to a variety of projects to support clients' need from development of health economic models for HTA submission purposes to payer tools for engagement with national and local payers. Her expertise also stretches to mapping studies and value frameworks in the cell, gene and rare diseases spaces. Aurelie has broad knowledge of HTA methods and of a variety of statistical software packages.
Rachael Miller
Rachael Miller
Rachael has been involved with a range of projects at PHMR and has experience conducting multiple stages of systematic reviews and working with meta-analyses. Previous experience in clinical trial management has also allowed her to develop skills in stringent data analysis, leadership and communication with commercial and academic sponsors, as well as clinical trial patients.
Anne-Sophie Moutié
Anne-Sophie has a wide-ranging experience of health economics and HTA in a range of settings including consultancies, hospitals, pharmaceutical companies and governmental bodies. Such wide-ranging experience has provided her with an in-depth understanding of HTA and reimbursement of pharmaceuticals. Anne-Sophie has developed many HTA submissions for the French HAS (Haute Autorité de Santé) for a range of new therapies including for oncology and orphan designation treatments on behalf of leading pharmaceutical companies. Prior to joining PHMR, Anne-Sophie worked at the Health Products Economics Committee (CEPS) of the French Ministry of Health where she developed valuable insight and experience in pricing processes and negotiations, and evaluation of economic dossiers.
Rachel Payne
Rachel Payne
Rachel is involved in a broad range of projects at PHMR but is largely responsible for managing the development of comprehensive, impactful, and strategic value communications to support in HTA submissions. She has experience in global value dossier development, value messages, treatment landscape analysis, reimbursement pathway mapping, literature reviews, peer-reviewed manuscript development, and stakeholder engagement through advisory boards and interviews. She has knowledge of multiple therapeutic areas including inflammatory bowel disease, anca-associated vasculitis, renal disease, and orphan diseases, and an has extensive background in nutraceuticals research. Rachel holds a PhD in Biological Psychology from Northumbria University.
Ally Robert
Ally is involved in a variety of projects at PHMR to help clients achieve optimal pricing and reimbursement. She has substantial experience in targeted and systematic literature reviews, research and data interpretation, and communicating complex information in slide decks and scientific reports. Ally has delivered multiple project types including reviews of clinical efficacy, burden of illness and HTA processes, mapping of pricing and reimbursement pathways, treatment landscape analysis, stakeholder interviews, strategic recommendations, value message development, and global value dossiers. She has disease area experience in oncology, infectious disease, chronic kidney disease, chronic inflammatory and autoimmune conditions, muscle wasting, and rare diseases. Ally holds a PhD in cellular biology and tissue engineering from Durham University.
Philip Ruane
Philip has significant experience of conducting systematic literature reviews, including data extraction, interpretation, and the communication of results aiming to support HTA submission and for external publication. Philip has contributed to reviews focusing on the clinical effectiveness of interventions as well as the burden of chronic conditions on patients and their caregivers. He has knowledge of several therapeutic areas including oncology, anca-associated vasculitis, and cystic fibrosis.
Caroline Shaw
Caroline Shaw
Caroline has been involved in conducting systematic and pragmatic literature reviews of clinical efficacy, economic evaluations, health-related quality of life and burden of illness, to support market access strategies. She has experience in all aspects of the review process, including developing protocols, screening, data extraction and report writing. She has also conducted primary market research with payers and KOLs to assess market access opportunities. Before joining PHMR, Caroline worked in academia in public health research, where she performed observational and interventional studies, as well as systematic and scoping reviews.
Alexandra Soare
Alexandra contributes to a broad range of projects at PHMR, including health state valuation, utility measurement, and mapping studies. She has provided clients with advice on strategies for collecting and analysing patient-reported outcomes data in disease areas characterised by fluctuating health-related quality of life. She has also applied her expertise in mapping approaches to support clients’ needs for obtaining utility data required for their HTA submissions. In addition, Alexandra has led work to assess partitioned survival models and Markov models in the context of advanced non-small cell lung cancer. She has an MSc in Health Economics and Decision Modelling from the University of Sheffield.
Elaine Stamp
Elaine Stamp
Elaine is a medical statistician with extensive experience of statistical input into clinical trials and large public health projects including development of protocols and statistical analysis plans as well as complex data analysis. At PHMR, Elaine's focus has been real-world evidence synthesis and indirect treatment comparisons, working to deliver statistical evidence used to support HTA submissions and inform client decisions around drug efficacy. Elaine is experienced in managing large data sets including patient-level health records and hospital episode statistics and has used these to inform clients on burden of disease and prescribing behaviours. Elaine has published in several peer-reviewed journals and is proficient in the use of advanced statistical software including R, Stata and WinBUGS. Elaine holds an MMathStat from Newcastle University.
Craig Tallentire
Craig has extensive experience in conducting systematic and pragmatic literature reviews of clinical and economic evidence alongside quantitative data analyses used to inform HTA submissions and other market access and reimbursement activities. Craig has also been involved in the development of value stories and global value dossiers, ultimately helping our clients build value for their products. He has experience in several disease areas including oncology, epilepsy, hyperkalaemia, and genetic disorders, and has published peer-reviewed research on neuroendocrine tumours. Craig holds a PhD in the broad area of food sustainability from Newcastle University.
Dimitris Tzelis

Dimitris is a health economist, with broad experience in economic evaluations of therapeutic and diagnostic interventions. He has led and contributed to the conceptualisation and development of cost-effectiveness and budget impact models, in a wide range of software. Dimitris has completed a number of projects for a diverse range of funders and clients including research foundations, pharmaceutical, and medical device companies. He also has conducted systematic literature reviews, and diagnostic meta-analyses, and has broad knowledge of HTA methods and processes. His work covers a wide range of disease areas including oncology, mental health, metabolic diseases, and rare diseases.

Sophie Walker
Sophie has contributed to a variety of projects including systematic and targeted literature reviews to inform HTA. She has substantial experience in communicating complex information in the form of impactful slide decks and concise global value dossiers. Sophie has worked on multiple project types including treatment landscape analyses, mapping of HTA and reimbursement pathways for rare diseases, and developing recommendations for capturing patient-reported data based on global HTA strategies. Sophie’s interest in market access has led her to coordinate the PHMR monthly market access alerts. She has also worked with clients to publish peer-reviewed research and poster presentations which have been presented at international conferences. She has knowledge of therapeutic areas including oncology, age-related disease, early development, chronic kidney disease and rare diseases. Sophie holds an MRes in Ageing & Health.
Catherine Watson
Catherine has contributed to a wide range of clinical and economic literature reviews adopting both pragmatic and systematic approaches. She has supported projects across several therapeutic areas, including oncology, epilepsy, and inflammatory bowel disease, applying extensive prior experience from a clinical trial background. Catherine has assisted in the publication of peer-reviewed research on neuroendocrine tumours and holds a PhD in neuroscience from Newcastle University.
Michael White
Michael has experience in developing communications to demonstrate product value such as evidence-based dossiers. He also has experience in conducting systematic and targeted literature reviews, including data interpretation and synthesis as well as communicating evidence in the form of slide decks, scientific reports, and peer-reviewed manuscripts. Michael has delivered on a range of projects, including reviews of clinical efficacy and burden of illness to support HTA submission and strategic recommendation development. He has knowledge in several disease areas, including oncology, chronic kidney disease, anca-associated vasculitis, diabetes, and cystic fibrosis. Michael has PhD in cellular and molecular biology from Newcastle University.
Tibi
Tibi has a part-time role at PHMR. She has expertise in methods for improving health and wellbeing outcomes in workplace settings. Outside of PHMR, Tibi can usually be found networking at nearby Hampstead Heath.
Market access alerts
Our market access alerts are hand-picked items of breaking pricing, reimbursement and market access news.

Alerts